Medical Research Network Acquired by IMA Group, Broadening Its Scope in Healthcare Sector
The IMA Group, a leading independent provider of outsourced healthcare evaluation and clinical research services, has made a strategic move to strengthen its position in the CNS (central nervous system) research arena. The acquisition of Medical Research Network (MRN) LLC, a clinical research site in New York City specializing in psychiatry and neurology trials for central nervous system disorders, is set to bolster IMA’s capacity and footprint in this critical therapeutic area[1][2].
This acquisition marks IMA’s second research site in New York City and its first East Coast location focused on CNS trials. The move complements existing CNS research centers in Phoenix, Las Vegas, and Albuquerque, expanding IMA’s nationwide presence in the field[1][2].
Dr. Michael R. Liebowitz, MD, the founder, CEO, and Principal Investigator of MRN, leads a team of experienced investigators. With over 30 years of experience in researching and treating anxiety, phobic, and affective disorders, Dr. Liebowitz brings a wealth of expertise to IMA’s network[2]. By incorporating MRN’s team, IMA aims to reduce time to first patient enrollment and ensure high-quality data capture[1][2].
The integration preserves MRN’s leadership and expertise, with the New York-based site continuing to operate under its current name and leadership after the acquisition. This continuity supports ongoing specialized research into CNS disorders such as anxiety, OCD, and affective disorders, leveraging Dr. Liebowitz’s deep expertise[2].
The acquisition aligns with IMA’s broader growth strategy of combining organic growth with acquisitions, reinforcing its status as one of the leading independent clinical research providers focused on CNS and behavioral health services[1][2]. This strategic move is expected to improve the speed, scale, and quality of CNS trials conducted by IMA, thereby supporting the development of new therapies for CNS disorders and advancing research capabilities in this area[1][2][4].
In summary, the acquisition of MRN by IMA Group signifies a significant step forward in the field of CNS research. The integration strengthens IMA’s ability to deliver efficient CNS trials, ensuring quality data capture, and positioning the company as a key player in the development of new treatments for CNS disorders.
[1] IMA Group Press Release. (2022). IMA Group Acquires Medical Research Network LLC. Retrieved from https://www.imagroup.com/news/ima-group-acquires-medical-research-network-llc/
[2] Medical Research Network. (n.d.). About MRN. Retrieved from https://www.mrnresearch.com/about-mrn/
[3] Medical Research Network. (n.d.). Our Team. Retrieved from https://www.mrnresearch.com/our-team/
[4] IMA Group. (n.d.). CNS Research. Retrieved from https://www.imacns.com/
- The acquisition of Medical Research Network (MRN) by The IMA Group will potentially bolster the latter's research in the mental health and neurological disorders sector, by leveraging MRN's focus on psychiatry and neurology trials for central nervous system disorders.
- The integration of MRN's expertise into IMA's health-and-wellness network could facilitate advancements in the development of new therapies for central nervous system disorders, through reduced time to first patient enrollment and ensuring high-quality data capture.
- With the addition of MRN, IMA Group is positioned to expand its footprint in the finance and business sector, as part of its overarching growth strategy to become a leading independent provider of clinical research services in the field of central nervous system disorders and behavioral health.
- This technological integration will also enhance IMA's capacity in the medical-conditions field, by broadening its nationwide presence and providing a stronger foundation for conducting research into a variety of CNS disorders, such as anxiety, OCD, and affective disorders.
